Iasoo Bio Enters IPO Tutoring with $70M+ Series C1 Funding and Submits Prospectus Highlighting Lead Candidate Ixazomib Injection

On April 4, 2023, the China Securities Regulatory Commission (CSRC) announced on its official website that the registration for the listing guidance of Nanjing IASO Biotherapeutics Co., Ltd. (referred to as "IASO Bio") has been accepted by the CSRC. The guiding institution is CITIC Securities, and the dispatched institution is the Jiangsu CSRC.

Source of the image: Official website of the CSRC

The IPO coaching work arrangement for IASO Bio is as follows, according to the coaching filing report:

Official website information shows that IASO Bio is a biopharmaceutical company in the clinical stage, dedicated to the development of innovative cell-based drugs. The company's innovation is based on the development of hematological tumor cell drugs and antibody drugs, expanding into solid tumors and autoimmune diseases. It possesses a complete, full-process platform capability from early discovery, regulatory submission, clinical development, to commercial production. This includes multiple technical platforms such as a fully human antibody discovery platform, high-throughput CAR-T drug optimization platform, universal CAR technology platform, manufacturing technology platform, and clinical translational research platform.

IASO Bio currently has 10 varieties in different stages of development. The most advanced candidate product, Ixal-cel Injection, has had its New Drug Application (NDA) officially accepted by the National Medical Products Administration (NMPA) and has been granted priority review status. It has also received FDA approval for registration clinical trials for the treatment of relapsed/refractory multiple myeloma. This product was successively included by the NMPA in the "Breakthrough Therapy Designation" category and granted "Orphan Drug Designation (ODD)" by the FDA. In addition to multiple myeloma, the Investigational New Drug (IND) application for expanded indications of Ixal-cel Injection - for antibody-mediated Neuromyelitis Optica Spectrum Disorder (NMOSD) - has been approved by the NMPA. The company’s independently developed innovative candidate product CT120 (fully human CD19/CD22 dual-target CAR-T cell injection) has entered the clinical research stage, with indications for CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and relapsed/refractory acute B lymphoblastic leukemia (B-ALL), and has been granted "Orphan Drug Designation (ODD)" by the FDA.

According to the official website, Dr. Wang Wen joined IASO Bio in March 2020 and currently serves as the company's Chief Executive Officer.

Dr. Wang Wen obtained a Bachelor of Medicine (B.M.) in Clinical Medicine from Anhui Medical University and worked as an orthopedic resident and attending physician at the Shanghai Integrated Traditional Chinese and Western Medicine Hospital. He later earned a Master of Medicine (M.M.) in Human Anatomy from Tongji University, a Medical Doctorate (M.D.) in Surgery from Tongji University/Germany’s Universität Würzburg, and a Ph.D. in Molecular Biology from the University of Aberdeen in the UK. He then served as a postdoctoral researcher at the University of Connecticut Health Center and has published over 20 SCI papers related to cell therapy in journals such as *Clin Cancer Res* and *Blood*.

Dr. Wang Wen joined the industry in 2013 and has served as Medical Director, Senior Director of Clinical Development, and Executive Director of Clinical Science at Cellular Biomedicine Group (Nasdaq: CBMG), JW Therapeutics Co., Ltd. (HKEX: 02126), and Simcere Pharmaceutical Group (SEHK: 02096). Since 2006, he has been engaged in cell therapy for over a decade and successfully led the filing of China's first CAR-T clinical trial targeting CD19 as a key project member. In March 2020, Dr. Wang Wen assumed the role of Chief Medical Officer at IASO Bio, leading the clinical development team to rapidly advance the CT103A clinical trial program. In April 2021, Dr. Wang Wen officially became the Chief Executive Officer of IASO Bio, taking full responsibility for the company’s operations and management.

PharmaInvest, a pharmaceutical data platform by PharmCube, shows that IASO Bio has completed several rounds of financing totaling over 100 million US dollars.